TB-500 — the actin-regulating peptide, explained

TB-500 is the working name for a 17-amino-acid synthetic fragment of thymosin β4 (Tβ4), a 43-residue actin-sequestering peptide first isolated from bovine thymus in the 1960s. TB-500 contains the actin-binding portion of the parent molecule and is used as a research tool across soft-tissue repair, angiogenesis, and cell migration literature. In the peptide-research community it is most often co-studied with BPC-157 as the "recovery stack" — the two peptides engage overlapping but distinct repair pathways. This primer covers the molecule, the mechanism, the published thymosin β4 research literature, the TB-500 vs full-length thymosin β4 distinction, administration routes, and what researchers should know.

The molecule, and the Tβ4 distinction. Native thymosin β4 is a 43-amino-acid peptide with molecular weight approximately 4963 Da. TB-500 is a 17-residue fragment corresponding to the central actin-binding region of the parent molecule (roughly residues 17-23 of the native sequence, extended), molecular weight approximately 1800-1900 Da depending on exact synthesis. The distinction matters because the published clinical and preclinical literature covers both — some studies are on full-length Tβ4 (clinically researched in products like RGN-259 for corneal healing and RGN-137 for wound healing), while others use TB-500 specifically. When reading the literature, pay attention to whether a paper refers to "thymosin β4," "Tβ4," or "TB-500" — these are related but not strictly interchangeable.

Mechanism of action. Thymosin β4's best-established biological role is actin sequestration — it binds monomeric G-actin at a 1:1 stoichiometry, preventing polymerization into filamentous F-actin until the cell needs to assemble cytoskeleton. This role makes Tβ4 a central regulator of cell migration, shape change, and cytokinesis. Beyond actin binding, Tβ4 has been shown to promote angiogenesis (new blood vessel formation via VEGFR2-independent pathways), reduce inflammatory cytokine output in macrophages, and accelerate soft-tissue repair in multiple animal models. The actin-sequestration activity is the structural core; the other effects are downstream or pleiotropic.

Published literature — primary sources. The most-cited modern review is Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Indications for its future as a therapeutic. Expert Opin Biol Ther. 2012;12(1):37-51 (doi: 10.1517/14712598.2012.634793) — co-authored by Allan Goldstein, who discovered thymosin β4, and covers the full arc from discovery through 2012 clinical work. For corneal wound-healing research specifically, Sosne G et al. Thymosin β4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-299 is the foundational animal model paper.

What's been studied — honestly. The preclinical literature is broad: cardiac repair after infarction (mouse), corneal wound healing (rat, rabbit, human), dermal wound healing (rodent and some human pilot), Achilles tendon healing (rat), liver regeneration (rat), and angiogenesis in multiple models. Full-length Tβ4 has been in Phase II and Phase III human clinical trials for corneal healing (RGN-259) and for dry eye disease — these are the most developed human datasets. TB-500 specifically (the shorter fragment) has a thinner independent human dataset, with most of the human evidence coming from the parent full-length peptide. Serious readers should treat the TB-500 and Tβ4 literatures as related but separate when evaluating specific claims.

The BPC-157 + TB-500 co-study rationale. In recovery-research protocols these two peptides are commonly dosed together on the hypothesis that they engage complementary repair pathways — BPC-157 operates predominantly through the VEGFR2-Akt-eNOS axis (angiogenesis driven by nitric oxide) while TB-500 operates through actin cytoskeleton regulation (cell migration, not just vessel formation). The combined effect on soft-tissue repair in rodent models exceeds either peptide alone in several published comparisons. Vivaprime offers a pre-dosed combination pen for this protocol, with each compound also available separately for designs that require dose independence.

Administration routes and dose ranges. TB-500 has been studied via subcutaneous and intramuscular injection (the dominant research routes), intravenous (some cardiac-research studies), and intranasal (emerging). Published rodent protocols use doses in the 100-2000 μg/kg range administered twice-weekly over multi-week protocols. Human pilot studies have used milligram-scale doses (typically 2-10 mg per injection, twice weekly tapering to weekly). As with BPC-157, dose extrapolation between species is not fully solved for this peptide class, and research-context users should anchor to specific published models rather than scale aggressively.

Storage, stability, and handling. Lyophilized TB-500 is stable at 2–8 °C for extended periods. In solution, stability varies by buffer and pH — reconstituted vials in bacteriostatic water should typically be used within 28 days at 2–8 °C. The pen format eliminates reconstitution, with the solvent system factory-tested for in-use stability. Do not freeze. Protect from light. A pen left at room temperature for more than a few hours should be refrigerated and the usable window recalculated.

What the COA should say. A batch-specific COA for TB-500 should include (1) identity confirmation by HPLC-MS against the theoretical mass of the specific 17-residue fragment (~1800-1900 Da; exact value depends on the published TB-500 sequence the manufacturer follows — there is some sequence variation across "TB-500" products on the market, which is a separate reason to always read the COA), (2) purity by reverse-phase HPLC-UV at 214 nm ≥ 98.0%, (3) residual solvent profile per ICH Q3C, (4) endotoxin by LAL in EU/mg. The COA should explicitly state the amino acid sequence used — this is particularly important for TB-500 given the sequence variance across suppliers.

Research-use only. Vivaprime supplies TB-500 as research reference material for qualified researchers engaged in in-vitro laboratory work. Neither TB-500 nor full-length thymosin β4 has been approved by the FDA for any therapeutic indication. TB-500 is on the WADA (World Anti-Doping Agency) prohibited list for athletic use — this is worth knowing if a research context overlaps with athletic testing. Nothing on this page constitutes a therapeutic, diagnostic, or consumption recommendation. Purchasers affirm the research-use agreement at checkout.